Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Checkmate Pharmaceuticals, Inc. (CMPI : NSDQ)
 
 • Company Description   
Checkmate Pharmaceuticals Inc. is a clinical stage biotechnology company. It is focused on developing proprietary technology to harness the power of the immune system to combat cancer. The company's product candidate includes CMP-001, which is in clinical stage. Checkmate Pharmaceuticals Inc. is based in Cambridge, United States.

Number of Employees: 30

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.46 Daily Weekly Monthly
20 Day Moving Average: 592,357 shares
Shares Outstanding: 22.04 (millions)
Market Capitalization: $230.52 (millions)
Beta: -4.84
52 Week High: $10.48
52 Week Low: $2.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 334.02% 375.57%
12 Week 222.84% 250.29%
Year To Date 264.46% 333.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
245 MAIN STREET 2ND FLOOR
-
CAMBRIDGE,MA 02142
USA
ph: 617-682-3625
fax: -
rdolski@checkmatepharma.com http://www.checkmatepharma.com
 
 • General Corporate Information   
Officers
Alan Bash - Chief Executive Officer; President and Director
Mike Powell - Chairman and Director
Robert Dolski - Chief Financial Officer
Peter Colabuono - Director
Keith Flaherty - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 162818108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 22.04
Most Recent Split Date: (:1)
Beta: -4.84
Market Capitalization: $230.52 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.19
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -12.31%
vs. Previous Quarter: -17.74%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -83.92
12/31/21 - -68.54
09/30/21 - -56.99
ROA
03/31/22 - -74.99
12/31/21 - -63.05
09/30/21 - -53.17
Current Ratio
03/31/22 - 5.20
12/31/21 - 7.89
09/30/21 - 11.35
Quick Ratio
03/31/22 - 5.20
12/31/21 - 7.89
09/30/21 - 11.35
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.50
12/31/21 - 3.21
09/30/21 - 3.77
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©